The Pharmacogenomic Testing (PGx) Project involves a partnership between the Ohio Department of Medicaid (ODM), the Government Resource Center (GRC), the Ohio State University Wexner Medical Center, and Northeast Ohio Medical University to conduct Medicaid claims data analyses as requested by ODM to support efficient and effective administration of the Medicaid program.
The goal of this project is to assess the potential benefit of pharmacogenomics testing to the Medicaid program using faculty expertise from the Ohio State University College of Medicine, the Ohio State University Wexner Medical Center, and Northeast Ohio Medical University in psychiatry, internal medicine, and pharmacy.
The project includes:
- An estimate of the potential benefit to Medicaid enrollees impacted by the genotype testing
- Potential cost-effectiveness to the Medicaid program of covering genetic testing for specific high frequency psychotropic medications
- A proposed methodology for a limited cost-effectiveness application focusing on Medicaid population
- Policy considerations for potentially generalizing genotype testing benefits for other Medicaid-designated programs
This work will culminate in a proposed methodology for a conducting a pilot test to evaluate the cost-effectiveness of implementing pharmacogenomics testing for psychotropic medications prescribed to adolescents and adults in the Ohio Medicaid program.